Skip to main content

Table 2 Association between baseline HOMA-IR and long-term cardio-renal outcomes

From: Insulin resistance, kidney outcomes and effects of the endothelin receptor antagonist atrasentan in patients with type 2 diabetes and chronic kidney disease

Outcome

n/N events (%)

Model 1

p value

Model 2

p value

Model 3

p value

HR (95% CI)

HR (95% CI)

HR (95% CI)

Cardiorenal outcomes

 Tertile 1

27/339 (8.0%)

(reference)

 

(reference)

 

(reference)

 

 Tertile 2

37/332 (11.1%)

1.31 (0.79–2.17)

0.289

1.41 (0.84–2.39)

0.197

1.74 (1.01–3.01)

0.046

 Tertile 3

39/328 (11.9%)

1.44 (0.88–2.35)

0.149

1.64 (0.96–2.81)

0.072

2.29 (1.28–4.09)

0.005

 p value for trend across tertiles

NA

1.19 (0.94–1.51)

0.154

1.27 (0.98–1.65)

0.076

1.49 (1.12–1.97)

0.006

 per log unit increase

NA

1.13 (0.95–1.35)

0.163

1.19 (0.99–1.43)

0.069

1.32 (1.09–1.60)

0.004

Renal composite or all-cause mortality

 Tertile 1

23/343 (6.7%)

(reference)

 

(reference)

 

(reference)

 

 Tertile 2

29/340 (8.5%)

1.20 (0.69–2.10)

0.511

1.25 (0.70–2.24)

0.453

1.40 (0.76–2.56)

0.278

 Tertile 3

34/333 (10.2%)

1.48 (0.87–2.51)

0.149

1.61 (0.89–2.90)

0.116

2.06 (1.09–3.88)

0.026

 p value for trend across tertiles

NA

1.22 (0.93–1.58)

0.145

1.27 (0.95–1.70)

0.110

1.44 (1.05–1.97)

0.023

 per log unit increase

NA

1.12 (0.93–1.36)

0.240

1.16 (0.95–1.43)

0.151

1.25 (1.01–1.55)

0.037

Renal composite

 Tertile 1

16/350 (4.6%)

(reference)

 

(reference)

 

(reference)

 

 Tertile 2

23/346 (6.6%)

1.38 (0.72–2.64)

0.331

1.46 (0.72–2.93)

0.293

1.87 (0.90–3.88)

0.093

 Tertile 3

23/344 (6.7%)

1.48 (0.78–2.81)

0.235

1.51 (0.71–3.18)

0.281

2.49 (1.11–5.60)

0.028

 p value for trend across tertiles

NA

1.20 (0.88–1.64)

0.244

1.21 (0.84–1.74)

0.305

1.55 (1.05–2.30)

0.029

 per log unit increase

NA

1.09 (0.87–1.37)

0.443

1.11 (0.87–1.43)

0.406

1.30 (1.00-1.68)

0.048

CV composite

 Tertile 1

12/354 (3.4%)

(reference)

 

(reference)

 

(reference)

 

 Tertile 2

15/354 (4.2%)

1.22 (0.57–2.62)

0.609

1.42 (0.65–3.11)

0.385

1.61 (0.71–3.66)

0.258

 Tertile 3

16/351 (4.6%)

1.34 (0.63–2.84)

0.445

1.61 (0.72–3.62)

0.249

1.88 (0.78–4.51)

0.160

 p value for trend across tertiles

NA

1.15 (0.80–1.67)

0.448

1.26 (0.85–1.88)

0.253

1.35 (0.88–2.07)

0.167

 per log unit increase

NA

1.17 (0.89–1.52)

0.256

1.25 (0.95–1.66)

0.116

1.34 (0.99–1.81)

0.060

  1. Note:
  2. Model 1 covariates: age, sex, treatment assignment (Atrasentan or Placebo)
  3. Model 2 covariates: age, sex, treatment assignment (Atrasentan or Placebo), race, BMI, eGFR, log(UACR), SBP, DBP
  4. Model 3 covariates: age, sex, treatment assignment (Atrasentan or Placebo), race, BMI, eGFR, log(UACR), SBP, DBP, hemoglobin, insulin use, cardiovascular disease history, log(BNP)
Back to article page

Cardiovascular Diabetology

ISSN: 1475-2840